CelLBxHealth partners with Royal Marsden on CTC-DNA study in advanced lung cancer

ANGLE plc ( (GB:CLBX) ) has shared an update.

CelLBxHealth has entered a research collaboration with The Royal Marsden NHS Foundation Trust to evaluate circulating tumor cell DNA profiling in 200 patients with advanced non-small cell lung cancer whose standard circulating tumor DNA tests fail to identify actionable mutations. The single-timepoint study, embedded in an existing ctDNA testing trial, aims to determine whether reflex CTC-DNA analysis can uncover additional clinically relevant genomic alterations, improve alignment with tissue profiling and broaden access to targeted therapies for an underserved patient group, potentially strengthening CelLBxHealth’s role in precision oncology and real-world clinical workflows.

Jointly led by CelLBxHealth’s head of R&D and The Royal Marsden’s genomics director, the study will share anonymised data between both organisations to support combined analysis and translational insights, with results expected by year end. By partnering with a globally recognised cancer centre and integrating CTC-DNA into established molecular testing pathways, CelLBxHealth is positioning its Parsortix-based technology as a complementary tool to standard liquid biopsy methods that could enhance treatment decision-making in advanced lung cancer.

The most recent analyst rating on (GB:CLBX) stock is a Buy with a £30.00 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:CLBX Stock Forecast page.

Spark’s Take on CLBX Stock

According to Spark, TipRanks’ AI Analyst, CLBX is a Neutral.

The overall stock score reflects significant financial challenges and bearish technical indicators, which are the most impactful factors. While recent corporate events and earnings call achievements provide some positive outlook, the financial and valuation concerns weigh heavily on the score.

To see Spark’s full report on CLBX stock, click here.

More about ANGLE plc

CelLBxHealth plc is a UK- and U.S.-based “CTC intelligence” company focused on innovative circulating tumor cell solutions for research, drug development and clinical oncology. Its patent-protected Parsortix platform isolates CTCs from blood and supports downstream imaging, proteomic and genomic analysis, monetised through product sales, laboratory services and lab-developed tests via partnerships and in-house development.

Average Trading Volume: 1,593,178

Technical Sentiment Signal: Strong Sell

Current Market Cap: £10.23M

Find detailed analytics on CLBX stock on TipRanks’ Stock Analysis page.